Current filters:  
Canada
IP
Patent
Canada
Fasken
On January 26, Health Canada issued a notice clarifying how a drug's "dormant" status on the drug product database may affect whether that drug...
Fasken (French)
Le 26 janvier, Santé Canada a publié un avis précisant comment l'état « dormant » d'un médicament dans la base de données sur les produits pharmaceutiques...
MLT Aikins LLP
Intellectual property (IP) rights are key assets for businesses, so it's important to know what types of rights are protectable and what actions that can be taken to enforce these rights.
Bereskin & Parr LLP
Scott MacKendrick and Andrew McIntosh's article "2023's Procedural Developments in IP Litigation" was published in the Toronto Law Journal.
Osler, Hoskin & Harcourt LLP
The Department of Finance opened two consultations on a potential patent box regime and on Canada's existing Scientific Research and Experimental Development (SR&ED)...
McMillan LLP
The "due care" standard is a relatively new one in Canadian patent law, and a recent (as of February, 2024) case from the Canadian Federal Court provides further guidance to patent applicants...
Oyen Wiggs Green & Mutala LLP
In Taillefer v. Canada (Attorney General), 2024 FC 259, the applicant unsuccessfully sought judicial review of a decision of the Commissioner of Patents denying a request to reinstate Canadian Patent 2,690,767...
Smart & Biggar
The intellectual property (IP) of your business has value. IP can take several forms, including patent and trademark registrations, or intellectual property rights...
Smart & Biggar
As previously reported, the Federal Court released a pair of decisions relating to paliperidone palmitate (Janssen's INVEGA SUSTENNA), finding in a summary trial that each of Pharmascience...
Smart & Biggar
In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate...
Smart & Biggar
On February 7, 2024, the Federal Court dismissed Takeda's action under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations in relation to dexlansoprazole.
Gowling WLG
Methods of medical treatment are considered to be an exception to patentable subject matter in Canada.
Smart & Biggar
AI technologies bring several new business opportunities, but they also bring a host of new legal questions, including in intellectual property law.
Lenczner Slaght LLP
If your 2024 has been too busy to keep up with caselaw, below we summarize and provide the key takeaways from pharmaceutical patent decisions...
Torys LLP
On February 1, 2024, the Federal Court of Appeal dismissed an appeal from a decision of the Federal Court, finding the claims of a patent to be valid and infringed.
Cassels
The Patented Medicine Prices Review Board Canada (PMPRB) published its "What We Learned Report" (Report) on February 15, 2024...
McMillan LLP
In early January 2024, the Canadian Intellectual Property Office (CIPO) and the Trade Commissioner Service (TCS) announced by way of a memorandum of understanding their continued collaboration ...
Lenczner Slaght LLP
It has been approximately six months since the Federal Court of Appeal's decision in Canada (Attorney General) v Benjamin Moore & Co(the "Benjamin Moore Appeal") was released...
Oyen Wiggs Green & Mutala LLP
The Federal Court of Canada has dismissed a patent infringement action by Takeda Canada Inc. against Apotex Inc. relating to the drug DEXILANT®, finding that the claims of Takeda's...
Torys LLP
The convenience of online shopping has given rise to more and more unapproved companies selling others' patented or trademarked products.
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Popular Contributors
Upcoming Events
Mondaq Social Media